- Active not recruiting
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
This study looks at existing medical records of people in Europe and Canada with a type of lung cancer called non-small cell lung cancer (NSCLC) who had surgery. It helps us understand how a treatment called immunotherapy is used before or after their operation, and how they got on.
For: Non-Small Cell Lung CancerUnited Kingdom - Active not recruitingPHASE3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This study is testing a new combination of medicines with chemotherapy for some upper gut cancers that have spread and can't be removed by surgery. It aims to see if the new combination works better than current treatments.
For: Advanced Upper Gastrointestinal Tract AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
This study looks at the long-term effects of a medicine called belzutifan for people with advanced cancers or cancers linked to Von Hippel-Lindau disease. It's for those already taking belzutifan in other trials. The aim is to see how long people live after starting this treatment.
For: Von Hippel-Lindau Disease · Malignant NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
This study looks at new drug Pumitamig with chemotherapy, or Nivolumab with chemotherapy, for advanced stomach, gastroesophageal junction, or oesophageal cancer. It aims to see how safe and effective these combinations are for people who haven't had treatment for their advanced cancer.
For: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE2
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
This study looks at a new treatment called RP1, by itself and with another drug called nivolumab. It's for people with certain advanced cancers like lung cancer, some skin cancers, and specific solid tumours that haven't responded well to previous treatments.
For: Non-Small Cell Lung Cancer (NSCLC) · Microsatellite Instability-High (MSI-H) · Non-melanoma Skin Cancer (NMSC)United States · France · Germany - Active not recruitingPHASE1
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
This study tests new ways to treat advanced pancreatic cancer. It combines a targeted drug (anetumab ravtansine) with immune-boosting medicines (nivolumab, ipilimumab) and standard chemotherapy (gemcitabine) to see if these combinations are safe and effective.
For: Pancreatic Adenocarcinoma · Stage II Pancreatic Cancer AJCC v8 · Stage III Pancreatic Cancer AJCC v8United States · Canada - RecruitingPHASE2
Using ctDNA to Determine Therapies for Lung Cancer
This study looks at a special blood test for lung cancer. If tiny bits of cancer DNA are found after surgery, researchers want to see if extra treatment can stop the cancer from coming back. It aims to help doctors decide who most needs further treatment.
For: Non Small Cell Lung Cancer · Complete Surgical Resection · Circulating Tumor DNACanada - RecruitingPHASE2
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
This study looks at combining nivolumab, an immunotherapy drug, with chemotherapy and then radiation for young people with nasopharyngeal cancer. Researchers want to see if this new treatment can fight the cancer effectively, understand its side effects, and potentially reduce radiation for children.
For: Stage II Nasopharyngeal Carcinoma AJCC v8 · Stage III Nasopharyngeal Carcinoma AJCC v8 · Stage IV Nasopharyngeal Carcinoma AJCC v8United States · Canada · New Zealand - Active not recruitingPHASE2
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
This study looks at treating advanced soft tissue sarcoma with a combination of two immunotherapy drugs (ipilimumab and nivolumab), alone or with an additional drug called cabozantinib, to see which works best.
For: Locally Advanced Extraskeletal Myxoid Chondrosarcoma · Locally Advanced Leiomyosarcoma · Locally Advanced LiposarcomaUnited States · Canada - Active not recruitingPHASE1, PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
This study is testing a new cell therapy called gavo-cel for advanced cancers like mesothelioma and ovarian cancer. It explores how well gavo-cel works, both alone and with other cancer drugs, in people whose tumours produce a specific protein called mesothelin.
For: Mesothelioma · Mesothelioma, Malignant · Mesothelioma; PleuraUnited States · Canada - Active not recruitingPHASE3
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
This study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) when used with chemotherapy for newly diagnosed, advanced Hodgkin lymphoma. It aims to see which combination works best at shrinking the cancer and keeping it away.
For: Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Ann Arbor Stage III Mixed Cellularity Classic Hodgkin LymphomaUnited States · Canada · Puerto Rico - RecruitingPHASE2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This study looks at adding a new drug, relatlimab, to current treatments for nasopharyngeal cancer that has come back or spread. The aim is to see if this addition can help keep the cancer from growing or spreading for longer.
For: Metastatic Nasopharyngeal Carcinoma · Recurrent Nasopharyngeal Carcinoma · Stage IV Nasopharyngeal Carcinoma AJCC v8United States · Australia · Canada - Active not recruitingPHASE3
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
This study looks at adding a new drug, nivolumab, to standard treatment for head and neck cancer after surgery. Researchers want to see if this combination improves health and prevents the cancer from coming back, without causing more problems.
For: Squamous Cell Carcinoma of Head and NeckFrance - Active not recruitingPHASE1, PHASE2
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
This study is looking at a new drug, BMS-986449, by itself and with another drug, nivolumab, for people with advanced cancers. Researchers want to see if these treatments are safe and effective. It's for patients whose cancer hasn't responded to usual treatments.
For: Advanced Solid TumorsUnited States · Belgium · France - RecruitingPHASE1
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
This study is looking at a new way to treat advanced liver cancer that can't be removed with surgery. It combines two existing cancer drugs, ipilimumab and nivolumab. Doctors want to find the safest and most effective dose when ipilimumab is given directly into the liver and nivolumab is given into the bloodstream.
For: Hepatocellular CarcinomaFrance - Active not recruitingPHASE1, PHASE2
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
This study is testing a new drug, BT7480, alone and with an existing drug, nivolumab, for advanced cancers that have a specific marker called Nectin-4. We want to find the safest dose, understand side effects, and see how well it works.
For: Advanced Solid TumorUnited States · United Kingdom - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
This study looks at a new treatment called VO with nivolumab for advanced melanoma that has grown despite earlier treatments. It compares this combination to standard treatments chosen by your doctor for people aged 12 and over.
For: Advanced MelanomaUnited States · France · Germany - RecruitingPHASE2
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
This study looks at new treatments for advanced liver cancer that hasn't responded to initial therapy. It combines a new medicine, visugromab, with existing treatments (nivolumab and lenvatinib) to see if this mix is more effective and safe than lenvatinib alone.
For: Unresectable or Metastatic Hepatocellular Carcinoma · Child-Pugh A Hepatocellular Carcinoma · Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 CompoundGermany · Italy - RecruitingPHASE2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
This study is for people with advanced lung cancer that has spread. It tests new treatments using a drug called Visugromab, combined with Nivolumab and sometimes Docetaxel, to see if they can work better than existing options.
For: Metastatic Non-Squamous Non-Small Cell Lung Cancer · Adult Solid TumorUnited States · Germany · Italy - Active not recruitingPHASE3
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
This study is for people with advanced kidney cancer (non-clear cell type) that hasn't spread too widely. It compares a new combination of drugs (XL092 + nivolumab) with a standard treatment (sunitinib) to see which works better. Participants haven't had prior cancer medicine for their advanced kidney cancer.
For: Non-Clear Cell Renal Cell CarcinomaUnited States · Argentina · Australia - RecruitingPHASE4
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
This study looks at how well a treatment combining two drugs, nivolumab and cabozantinib, works for older patients (70 and over) with advanced kidney cancer. It aims to see how patients respond to this treatment in real-life use.
For: Kidney Cancer · Renal Cell CancerFrance - Active not recruitingPHASE1
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
This study looks at new drug combinations for advanced melanoma with a specific gene change (NRAS mutation). It tests the safety and effects of belvarafenib, alone or with other medicines, for people who have already tried other treatments.
For: MelanomaUnited States · Australia · Canada - RecruitingPHASE3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This study compares a new treatment called IMA203 with standard care for advanced skin melanoma that has already been treated. Its main goal is to see if IMA203 is more effective and safe for patients who have limited treatment options.
For: Melanoma, Cutaneous MalignantUnited States · Canada · France - RecruitingPHASE1, PHASE2
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
This study looks at a new drug, mRNA-4359, by itself and with other cancer drugs. It aims to see if it's safe and what side effects it might have in people with advanced solid tumours, which are cancers that have spread.
For: Advanced Solid TumorsUnited States · Australia · Germany - Active not recruitingPHASE2, PHASE3
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This study looks at new treatments for advanced eye melanoma that has spread. It compares a combination of two drugs (IDE196 and crizotinib) with standard treatments to see which works best and is safest for patients.
For: Metastatic Uveal MelanomaUnited States · Australia · Belgium - RecruitingPHASE3
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
This study is looking into a new treatment called brenetafusp, combined with nivolumab, for advanced melanoma. We're comparing it to current standard nivolumab treatments to see if it works better for people in the UK whose melanoma hasn't been treated before.
For: Advanced MelanomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
This study looks at a new drug, Nivolumab, combined with standard treatment (ABVD) for Hodgkin lymphoma. The goal is to improve the chances of a cure, especially for people with higher-risk forms of the disease. It checks if adding Nivolumab helps when initial treatment doesn't fully clear the cancer.
For: Hodgkin LymphomaUnited States · Canada - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
For: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal CancerUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - Active not recruitingPHASE2
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
This study looks at new treatments for advanced endometrial cancer that has come back or spread. It tests if combining two drugs, cabozantinib and nivolumab, works better than nivolumab alone to shrink cancer and help people live longer. This could offer new hope for patients.
For: Advanced Endometrial Carcinoma · Metastatic Endometrial Carcinoma · Recurrent Endometrial CarcinomaUnited States · Canada - Active not recruitingPHASE3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
This study compares a new treatment, Volrustomig combined with standard chemotherapy, against existing treatments for advanced mesothelioma. It aims to see if the new combination is safer and more effective for patients whose cancer can't be removed by surgery.
For: Unresectable Pleural MesotheliomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
This study is testing two new drugs, nivolumab and ipilimumab, together for advanced liver cancer (hepatocellular carcinoma). It compares this combination to standard treatments (sorafenib or lenvatinib) to see if it helps people live longer. Participants haven't had prior treatment.
For: Hepatocellular CarcinomaUnited States · Argentina · Australia - RecruitingPHASE1
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This study is looking into a new treatment, BMS-986488, for advanced cancers. Researchers want to see if it's safe, tolerable, and effective, either on its own or with other medicines, for people whose cancer has spread or can't be removed with surgery.
For: Advanced Malignant TumorsUnited States · Australia · Canada - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
This study looks at new treatments (nivolumab, sometimes with ipilimumab, or nivolumab with chemotherapy) for people with a certain type of lung cancer before surgery. It aims to see if these treatments are safe and how well they work to fight the cancer earlier.
For: Non-Small Cell Lung CancerUnited States · Canada - Active not recruitingPHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations to treat advanced lung cancer. It compares two different drug mixes, each including chemotherapy, to see which works best and is safest for people with Stage IV or recurrent non-small cell lung cancer.
For: Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Metastatic Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
This study aims to see if a special ultrasound device, Exablate, can help standard cancer medicines work better for people with lung cancer that has spread to the brain. Researchers will compare this new approach to standard care alone.
For: Brain Tumor · Non Small Cell Lung CancerUnited States · Canada · South Korea - RecruitingPHASE2
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
This study is looking at adding a new drug called Nivolumab to standard chemotherapy for nasopharyngeal cancer. It aims to see if this combination helps more patients achieve a complete response, meaning the cancer is no longer detectable, especially when seen on scans.
For: Nasopharyngeal Carcinoma · Nasopharyngeal Cancer · Nasopharyngeal NeoplasmsGermany - RecruitingPHASE3
The Sagittarius Trial
This study looks at new ways to treat colon cancer after surgery to stop it coming back. It uses advanced tests called 'liquid biopsies' to help doctors choose the best treatment for each person, aiming for better results and fewer side effects.
For: Colon Cancer Stage II · Colon Cancer Stage IIIGermany · Italy · Spain - Active not recruitingPHASE3
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
This study looks at a new drug, nivolumab, for kidney cancer that hasn't spread. It compares surgery alone to surgery plus nivolumab to see if the drug can stop the cancer from coming back. It's a phase 3 trial, meaning it's in its later stages of testing.
For: Metastatic Renal Cell Carcinoma · Sarcomatoid Renal Cell Carcinoma · Stage II Renal Cell Cancer AJCC v7United States · Canada · Israel - RecruitingPHASE3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
This study compares a new drug called tepotinib with standard treatments for advanced lung cancer. It's for people whose cancer has a specific change (MET Exon 14 mutation) and has already been treated. The aim is to see if tepotinib works better to stop the cancer from growing.
For: Advanced Non Small Cell Lung Cancer · MET Exon 14 MutationFrance - RecruitingPHASE2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
This study looks at new ways to treat a rare type of skin cancer called mucosal melanoma, found inside the body. It tests if a drug called nivolumab, alone or with another drug called cabozantinib, can stop the cancer from coming back after surgery or help those where surgery wasn't enough.
For: Anal Melanoma · Bladder Melanoma · Cervical MelanomaUnited States · Canada - AuthorisedTherapeutic use (Phase IV)
Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
This study looks at how different doses of nivolumab, a cancer medicine, work in people with melanoma or kidney cancer. It wants to find the best dose to keep the medicine effective while perhaps using less. This could make treatment easier and more affordable.
For: Melanoma, Renal cell carcinomaNetherlands - Active not recruitingPHASE3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
This study looks at a new immune-boosting medicine called Nivolumab for people who have had surgery for bladder or kidney drainage system cancer. It compares Nivolumab to a dummy drug to see if it's safe and helps stop the cancer from coming back.
For: Various Advanced CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Study of Novel Treatment Combinations in Patients With Lung Cancer
This study looks at new drug combinations to treat lung cancer. It has three parts: for cancer that has spread, cancer that has grown despite previous treatment, and earlier-stage cancer that can be removed by surgery.
For: Lung Cancer · Advanced or Metastatic Non-Small-Cell Lung Cancer · Resectable Non-Small-Cell Lung CancerUnited States · Brazil · Hong Kong - Active not recruitingPHASE2, PHASE3
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
This study is looking at a new combination of medicines, relatlimab and nivolumab, for advanced melanoma. It aims to see if this combination works better than nivolumab alone for melanoma that has spread or can't be removed by surgery.
For: MelanomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This study is testing a new drug, BT5528, for advanced cancers like ovarian, lung, and breast cancer. We want to find a safe dose, understand side effects, and see how well it works, sometimes given with another drug called nivolumab.
For: Advanced Solid Tumor Historically Known for High EphA2 Expression · Urothelial Cancer · Ovarian CancerUnited States · Belgium · South Korea